Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 18;25(1):465.
doi: 10.1186/s12882-024-03901-7.

Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review

Lu Wang #  1 , Yinglin Wang #  1 , Quan Zhao  2
Affiliations

Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review

Lu Wang et al. BMC Nephrol. .

Abstract

Introduction: Chronic kidney disease is a significant public health issue. Dapagliflozin has been shown to improve the quality of life for patients with chronic kidney disease. This review aimed to systematically assess the cost-effectiveness of adding dapagliflozin to standard care compared with standard care alone for treating chronic kidney disease.

Methods: The relevant studies were searched in PubMed, Web of Science, Scopus, Embase, and Cochrane from the inception date to June 1, 2024. The titles, abstracts, and full texts were independently evaluated and screened by two authors. Additionally, the economic evaluation studies were assessed independently by two authors using the consolidated health economic evaluation reporting standards checklist.

Results: 14 studies were included which were about the economic evaluations of adding dapagliflozin in the treatment of chronic kidney disease. The minimum consolidated health economic evaluation reporting standards score for the studies was 0.77, indicating very good quality. Adding dapagliflozin to the standard of care would be more effective and cost-saving in Mexico, Malaysia, Canada, Thailand, and China. The highest incremental cost-effectiveness ratio of dapagliflozin ($67962.75/QALY) originated from the USA. According to the available studies, adding dapagliflozin to standard of care for the treatment of chronic kidney disease is considered cost-effectiveness from both the healthcare system and the payer's perspective.

Conclusion: Adding dapagliflozin to standard care in the treatment of chronic kidney disease is cost-effective from both the healthcare system and the payer's perspective in well-developed countries.

Keywords: Chronic kidney disease; Dapagliflozin; Economic evaluations; Standard care; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable. Human participant protection: This systematic review was limited to published research and did not involve human participants, and as such, human participant protection was not required.

Figures

Fig. 1
Fig. 1
PRISMA flow chart for study selection
Fig. 2
Fig. 2
Quality assessment results of the included studies
Fig. 3
Fig. 3
Incremental QALY and LYG of dapagliflozin plus standard therapy versus Standard therapy on the lifetime horizon
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Nava-Vargas MG, Arellano-Arteaga KJ, Cortés-Sanabria L, et al. Wcn23-1211 cost-effectiveness analysis of Dapagliflozin for Diabetic kidney disease in Mexico. Kidney Int Rep. 2023;8(3). 10.1016/j.ekir.2023.02.459.
    1. Wang L, Xu X, Zhang M, et al. Prevalence of chronic kidney disease in China: results from the Sixth China Chronic Disease and risk factor surveillance. JAMA Intern Med. 2023;183(4):298–310. 10.1001/jamainternmed.2022.6817. - PMC - PubMed
    1. Bello AK, Okpechi IG, Levin A, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382–95. 10.1016/S2214-109X(23)00570-3. - PubMed
    1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7–11. 10.1016/j.kisu.2021.11.003. - PMC - PubMed
    1. Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414–D22. 10.2471/BLT.17.206441. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources